Amgen's Imdelltra Shows Significant Survival Benefit in Small Cell Lung Cancer, Marking a 'Watershed Moment'

Amgen's Imdelltra (tarlatamab) has demonstrated a massive survival benefit in patients with small cell lung cancer (SCLC), with results from the DeLLphi-305 trial simultaneously published in The New England Journal of Medicine. This development is being hailed as 'transformational' for SCLC patients, as the Imdelltra regimen lowered the risk of disease progression or death by 66% compared to Imfinzi alone.